DEC 1 0 2007

OsteoSymbionics, LLC

1768 East 25th Street Cleveland, Ohio 44114

Contact Person

Ms. Cynthia Brogan, President

Phone: (216) 881-8500

e-mail: cb@osteosymbionics.com

Date Prepared

September_12, 2007

Device Name

Proprietary Name: OsteoSymbionics Patient-Specific Cranial Implant

Common Name: patient-specific cranial implant

Classification Name: "plate, cranioplasty, preformed, non-alterable," a

class II device in accordance with 21 CFR § 882.5330

Device Description

The OsteoSymbionics Patient Specific Cranial Implants are individually sized and shaped implantable prosthetic cranioplasty plates intended to fill defects in a specific patient's cranial/craniofacial skeleton. The implants are composed of polymethyl methacrylate and are fabricated using the patient's CT imaging data. The devices are provided non-sterile for sterilization prior to implantation and are attached to the

native bone with commercially available cranioplasty fasteners.

Indication for Use

The OsteoSymbionics Patient-Specific Cranial Implants are designed individually for each patient to correct defects in craniofacial bone.

Substantial Equivalence The OsteoSymbionics Patient-Specific Cranial Implants are substantially equivalent in terms of safety and effectiveness to the following legally

marketed devices:

Synthes Patient Specific Cranial/Craniofacial Implants - K033868

Synthes (USA)

Stryker® Patient Specific Polymer Implant - K043250

Stryker Liebinger

Codman Cranioplastic - K873689

Codman Division of Johnson & Johnson



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 1 0 2007

OsteoSymbionics, LLC % Ms. Cynthia Brogan President 1768 East 25th Street Cleveland, OH 44114

Re:

K072601

Trade/Device Name: OsteoSymbionics Patient-Specific Cranial Implant

Regulation Number: 21 CFR 882.5300

Regulation Name: Methyl methacrylate for cranioplasty

Regulatory Class: Class II Product Code: GXP, GXN Dated: September 12, 2007 Received: September 14, 2007

Dear Ms. Brogan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Cynthia Brogan

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Mark of Melkers

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

Indications for Use Statement 510(k) Number: _ Device Name: OsteoSymbionics Patient-Specific Cranial Implants Indications for Use: The OsteoSymbionics Patient Specific Cranial Implants are designed individually for each patient to correct defects in craniofacial bone. Over-The-Counter Use _ Prescription Use X AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE—CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of General, Restorative, and Neurological Devices

(Division Sign-Off)

510(k) Number <u><u><u><u>K07240</u></u>)</u></u>